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Abstract
Background and Aims: To reduce hepatitis C virus (HCV) transmission among people who 
inject drugs (PWID), Scottish Government-funded national strategies, launched in 2008, promoted 
scaling-up opioid substitution therapy (OST) and needle and syringe provision (NSP), with some 
increases in HCV treatment. We test whether observed decreases in HCV incidence post-2008 can 
be attributed to this intervention scale-up.
Design: A dynamic HCV transmission model amongst PWID incorporating intervention scale-up 
and observed decreases in behavioural risk, calibrated to Scottish HCV prevalence and incidence 
data for 2008/09.
Setting: Scotland, UK
Participants: PWID
Measurements: Model projections from 2008–2015 were compared with data to test whether 
they were consistent with observed decreases in HCV incidence amongst PWID while 
incorporating the observed intervention scale-up, and to determine the impact of scaling-up 
interventions on incidence.
Findings: Without fitting to epidemiological data post-2008/09, the model incorporating 
observed intervention scale-up agreed with observed decreases in HCV incidence amongst PWID 
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between 2008–2015, suggesting HCV incidence decreased by 61.3% (95% credibility interval 
45.1–75.3%) from 14.2/100pyrs (9.0–20.7) to 5.5/100pyrs (2.9–9.2). On average, each model fit 
lay within 84% (10.1/12) of the confidence bounds for the 12 incidence data points which the 
model was compared against. We estimate that scale-up of interventions (OST+NSP+HCV 
treatment) and decreases in high-risk behaviour from 2008–2015 resulted in a 33.9% (23.8–
44.6%) decrease in incidence, with the remainder (27.4% (17.6–37.0%)) explained by historical 
changes in OST+NSP coverage and risk pre-2008. Projections suggest scaling-up of all 
interventions post-2008 averted 1,492 (657–2,646) infections over 7-years, with 1,016 (308–
1,996), 404 (150–836) and 72 (27–137) due to scale-up of OST+NSP, decreases in high-risk 
behaviour, and HCV treatment, respectively.
Conclusions: Most of the decline in hepatitis C virus (HCV) incidence in Scotland between 
2008–2015 appears to be attributable to intervention scale-up (opioid substitution therapy and 
needle and syringe provision) due to government strategies on HCV and drugs.
Keywords
Hepatitis C; people who inject drugs; injecting drug users; opioid substitution therapy; needle and 
syringe programmes; Scotland
Introduction
Hepatitis C virus (HCV) is a blood-borne disease with high global burden(1), and a leading 
cause of death and morbidity(2,3). It is estimated that 90% of HCV infections in Scotland 
are acquired through injecting drug use(4), with people who inject drugs (PWID) harbouring 
a high burden of infection (54% sero-prevalence in 2008/09(5,6)).
Evidence suggests that needle and syringe provision (NSP) and opioid substitution therapy 
(OST) can reduce an individual’s risk of HCV acquisition(7), but little evidence exists of 
their impact at the population-level(8–11). Modelling has estimated the impact of these 
interventions on HCV transmission at the population-level(12,13), as well as the impact of 
HCV treatment as prevention(14,15), however no analyses have validated their projections 
against epidemiological data.
In Scotland, NSP and OST were introduced in the 1980s, increasing incrementally since 
then, with their scale-up credited to decreasing HCV prevalence amongst PWID in the 
1990s(16,17). However, HCV prevalence has remained high since then and new 
presentations for HCV-related liver failure/cancer have been increasing(4,5). Therefore, in 
2008, the Scottish government launched a national action plan for HCV, aiming to reduce 
HCV transmission amongst PWID alongside reducing HCV-related morbidity. The strategy 
was underpinned by additional investment above existing HCV funding (~100 million 
during 2008–15) and focussed on scaling-up harm reduction interventions (particularly 
providing needle/syringes and other injecting equipment) and HCV testing/treatment 
services(4,18). Contemporaneously, the Scottish Government published a new drug and 
alcohol strategy, setting out a programme to tackle Scotland’s drug problem and reduce 
waiting times for drug treatment; thus having the potential to impact the delivery of 
OST(19). Over the first 3 years of these strategies (2008/09 to 2011/12), the scale-up of high 
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coverage needle and syringe provision (high coverage NSP – defined as exchanging at least 
one sterile needle/syringe per injection) increased by 40%(5), OST coverage increased by 
30%(5), and annual numbers of HCV treatments doubled to 1,000(4), with almost half 
amongst current or temporarily ceased PWIDs (mostly on OST). Concurrently, a halving in 
HCV incidence occurred(5). However, there was no control comparison for this nationwide 
programme; and so it is difficult to determine whether this decrease in HCV incidence 
occurred due to the intervention scale-up, or would have occurred anyway. Similar issues 
have been addressed in the HIV-field by using modelling to determine whether observed 
changes in disease transmission are consistent with the scale-up of specific 
interventions(11,20–24).
We model the transmission of HCV among PWID in Scotland using data from national 
cross-sectional surveys carried out between 2008 and 2014. A dynamic, deterministic model 
is implemented to capture all intervention components and behavioural changes, enabling us 
to quantify how they may have affected transmission. Using synthesised evidence on the 
efficacy of NSP and OST(7), the model is used to test whether observed decreases in HCV 
incidence and prevalence amongst PWID from 2008–2015 are consistent with the scale-up 
of interventions over this period, and then quantify the impact of the national HCV and drug 
strategies that resulted in this scale-up. This dynamic transmission process is something that 
could not be tested with a statistical model.
Methods
Model description
A dynamic, deterministic mathematical model of HCV transmission amongst PWID was 
developed. The PWID population was stratified into current (had injected in the previous 
year) and temporarily ceased (had not injected in the previous year) PWID. These groups 
were divided into short-term (<1 year since onset), mid-term (1–9 years since onset) and 
long-term (≥10 years since onset) PWID, stratified into those on OST and high coverage 
NSP, as well as whether they were high-risk (defined as either currently homeless or 
injecting stimulants) or not (Supplementary Figure S1a).
PWID enter the model through initiating injecting into the current, short-term injecting 
group, and leave through permanently ceasing injecting (from the temporarily ceased 
groups) or through drug-related or non-drug related mortality (all groups). All PWID enter 
the model with no coverage of OST or high coverage NSP, with a time-varying proportion 
being high- or low-risk (see Model Parameterisation). PWID transition between different 
injecting, intervention and risk states at specified rates. All transitions are bi-directional 
except for those between injecting durations. All current PWID can temporarily cease 
injecting (more likely if on OST), with these PWID then either leaving the model due to 
permanently ceasing injecting or returning to currently injecting status.
The model is also stratified by HCV infection status (Supplementary Figure S1b), with all 
new PWID being susceptible to infection. The model simulates transmission of HCV 
amongst currently injecting PWID, with transmission occurring at a per-capita rate 
dependent on the injecting risk (high-risk or not), intervention status (OST and/or high 
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coverage NSP), and duration of injecting (Supplementary Materials for further details). 
Once infected, PWID either transition to the chronically infected group, or spontaneously 
clear infection, transitioning to the previously infected group. Due to uncertainty in the 
evidence(25–29), we assume that previously infected PWID are re-infected with the same 
risk as for primary infections of susceptible PWID. Chronically infected individuals can be 
treated, whereupon they either attain a sustained viral response (SVR) and move to the 
previously infected group, or transition to the treatment failure group. In the baseline model, 
treatment failures are not retreated. The model assumes that PWID mix to form transmission 
contacts, with a user defined proportion of these contacts being formed randomly 
proportional to the overall transmission risk of PWID in different sub-groups, and the 
remainder being formed assortatively (like-with-like) with PWID of the same duration of 
injecting (short-term, mid-term or long-term) or risk level (high- or low-risk).
Model parameterisation
The model was primarily parameterised and calibrated using data from four large surveys 
(n=2194–3315 for each survey) undertaken amongst people who had ever injected drugs 
(~80% had injected in the previous 6 months), recruited from ~100 (50% of all) sites 
providing injecting equipment across Scotland between 2008–2014: the Needle Exchange 
Surveillance Initiative (NESI) surveys(5,6,30). Data analyses were undertaken using Stata 
Version 14.2. Historical survey data, intervention output, and PWID size estimation data 
were also incorporated as described below, with the data sources described in the 
Supplementary Materials.
Risk-status parameters
Risk Status:  Post-2005, data from the NESI surveys and two other cross-sectional surveys 
conducted in Glasgow (2005 and 2007)(31) were used to estimate the proportion of PWID 
that were high-risk (defined by either being homeless in the past six months or currently 
injecting stimulants – both associated with increased HCV risk in the NESI datasets) for 
different durations of injecting. The prevalence of high-risk behaviours was greater in those 
with shorter rather than longer injecting durations, and so this was incorporated into the 
model.
Intervention parameters
OST Coverage:  We assumed OST started in 1985, in response to the spread of HIV 
infection among PWID. Estimates of OST coverage amongst PWID in Scotland between 
1995–2014 were derived from data on methadone prescriptions dispensed across 
Scotland(32–34), and self-reported survey data on OST uptake from Glasgow (2005)(31) 
and the NESI surveys. NESI data suggested higher OST coverage amongst those injecting 
for longer, which was incorporated into the model (Table S2).
NSP Coverage:  NSP coverage was estimated from the number of syringes distributed in 
Glasgow or nationally from 1988/89 to 2012/13(5,35–37), estimates of the number of PWID 
in Scotland(38), and the average injecting frequency while accounting for differences by 
OST status (from NESI) and the changing coverage of OST. Due to high NSP coverage 
across all injecting durations, we assumed the same coverage for all PWID.
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HCV Risk:  Data from a UK pooled analysis were used to parameterise the degree to which 
being on OST, high coverage NSP, or both reduces the risk of acquiring HCV(7,39). Using 
NESI, risk ratios were calculated for the increased risk of HCV acquisition associated with 
being homeless or injecting stimulants (denoted as high-risk), and for different durations of 
injection. These increases in risk status were not found to differ if adjusted for OST and high 
coverage NSP status.
HCV Treatment:  Pre-2002, PWID were not recommended for HCV treatment in the 
UK(40). Post-2002, data on the number of treatments in Scotland were used to estimate the 
number occurring amongst PWID(41). We calculated a weighted SVR rate and treatment 
duration based on the genotype distribution(42–44), and assumed that only PWID on OST 
are treated based on current HCV treatment/care pathways in Scotland(45).
PWID related parameters
Injecting Duration:  Data on injecting cessation (1/duration) and relapse were based on the 
Edinburgh Addiction cohort(46,47).
Probability distributions were attached to all uncertain model parameters and calibration 
data thought to affect the decrease in HCV prevalence and incidence. Parameter values and 
distributions used in the model are shown in Table 1, while calibration data from NESI are 
given in supplementary Table S2. More details on the model parameterisation is included in 
the Supplementary Materials.
Model calibration
A Bayesian model-fitting algorithm was used for model calibration. Five-thousand model 
parameter sets were randomly sampled from the parameter uncertainty distributions in Table 
1, and 5,000 HCV sero-prevalence estimates for current PWID in 2008/09.
Other parameters were not sampled, but estimated for each parameter set. Through fitting 
reduced sub-models to specific data quantities, estimates were generated for the: (1) rate 
PWID initiate injecting by fitting to the sampled PWID population size; (2 and 3) time 
varying recruitment rates onto OST and NSP by fitting to the sampled OST and high 
coverage NSP coverage for specified years (1985, 2005, 2008 and 2013/14 for OST; and 
1990, 2008 and 2011/12 for NSP); and (4) proportion high-risk when initiating injecting and 
transition rates from low to high-risk by fitting to the sampled proportion high-risk for 
specified years (1990, 2005, 2008 and 2013/14). See Supplementary Materials for more 
detail.
These fitted parameters, along with the initially sampled parameters, were used to calibrate 
the full model to the sampled HCV sero-prevalence amongst current PWID for 2008/09 by 
varying the overall transmission rate amongst PWID. These preliminary model fits to the 
overall HCV sero-prevalence in 2008/09 were compared against the HCV sero-prevalence 
amongst short-term PWID and incidence in current PWID, both from NESI in 2008/09. Any 
run that lay within the 95% confidence bounds for both quantities was accepted as a 
baseline model fit. From 5,000 sampled parameter sets, 581 baseline model fits were 
obtained, which were used for all subsequent analyses. It is noteworthy that the baseline 
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model fits were not calibrated to any HCV epidemiological data from later surveys, or mid-
term or long-term PWID. All model fitting used the lsqnonlin algorithm in MATLAB 2016a.
Model analyses
Projections from all baseline model fits were compared against all available NESI HCV 
incidence estimates (2008/09, 2010, 2011/12 and 2013/14) for short-term, mid-term and 
long-term PWID – in total 12 data points. This was done to assess whether the model 
replicated the observed decreases in these epidemiological measures while incorporating the 
observed scale-up of interventions and decrease in high-risk status over time. Specifically, 
we estimated the percentage of the 95% confidence intervals for these 12 data points that 
each baseline model fit lay within, and estimated the average of this across all baseline 
model fits.
We also generated model projections using all baseline model fits for a full counterfactual 
of no increase in intervention coverage (OST, NSP and HCV treatment) or decrease in high-
risk behaviour post-2008, and partial counterfactuals assuming one or more of the 
intervention components were at constant coverage post-2008. The full and partial 
counterfactuals were used to estimate the number of HCV infections averted due to each 
intervention component, and the relative change in HCV incidence that would have occurred 
without any changes in intervention coverage or high-risk behaviour post-2008. 95% 
credibility intervals (95%CrI) were produced using the 2.5 to 97.5 percentile range in the 
projections across the model fits.
Lastly, an analysis of co-variance (ANCOVA) was performed on the relative decrease in 
incidence between 2008–2015 when all interventions were scaled up, and on the number of 
HCV infections averted over this period compared to the full counterfactual. This 
determined the importance of uncertainty in different parameters to the variability in these 
outcomes by calculating the proportion of the sum of squares contributed by each 
parameter(48).
Results
Model comparison with available data
The baseline ‘intervention’ model accurately captures the overall (Figure 1, and by injecting 
duration–Figure S3) increasing trend in OST and NSP coverage, and decreasing trend in 
‘high-risk’ PWID between 2008/09–2013/14. Although not calibrated to HCV incidence 
data post-2008/09, Figures 2 and S4 show the model reproduces observed trends in HCV 
incidence from NESI between 2008–2014, overall and by different injecting duration 
categories. Indeed, on average, each baseline model fit lies within 84% (10.1/12) of the 
confidence bounds (95% confidence intervals) for the 12 incidence data points that the 
model was compared against – none of which were fit to. The model also, though to a lesser 
extent, reproduces the trends in HCV prevalence (Figure 2 and Figure S4).
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Impact of intervention
The model projects a mean baseline incidence of 14.2 per 100pyrs (95%CrI 9.0–20.7) 
amongst current PWID in 2008. When incorporating all changes in intervention coverage 
and high-risk status, the baseline ‘intervention’ model projects that between 2008–2015, 
HCV incidence amongst current PWID decreased by 61.3% (95%CrI 45.1–75.3%) to 5.5 
per 100pyrs (95%CrI 2.9–9.2) (Table 2). However, the counterfactual model suggests 
without this intervention scale-up or change in high-risk status since 2008, HCV incidence 
could still have decreased (Table 2 and Figures 3/S4) by a quarter (27.4%, 95%CrI 17.6–
37.0%) to 10.3 per 100pyrs (95%CrI 6.1–15.7) by 2015. Therefore, we estimate that 
increases in intervention coverage and decreases in high-risk status post-2008 resulted in an 
additional 33.9% decrease (95%CrI 23.8–44.6%) in HCV incidence. This translates to 1,492 
(95%CrI 657–2,646) HCV infections averted between 2008–2015 or 31.3% (95%CrI 16.1–
50.7%) of all HCV infections (Table 2) occurring over that period compared to the 
counterfactual model. Most of the HCV infections averted (66.8%, 95%CrI 39.9–83.7%) 
were due to scale-up in OST and NSP post-2008, which averted 1,016 (95%CrI 308–1,996) 
HCV infections, whereas HCV treatment averted 72 (95%CrI 27–137) infections (Table 2) 
with the remainder (404, 95%CrI 150–836) due to decreases in high-risk PWID.
ANCOVA analysis
ANCOVA analysis indicates that the largest contributor to the variability in the impact 
projections for HCV incidence came from uncertainty in the efficacy of being on both OST 
and NSP for reducing HCV acquisition risk (36% of the variation), and uncertainty in the 
efficacy of NSP alone (31% of variation). Uncertainty in the increased risk of transmission 
amongst short-term and mid-term PWID contributed 7% and 3% of the variation, 
respectively, whereas all other parameters contributed less than 3% (Supplementary Figure 
S5).
Variability in the number of infections averted was mainly due to uncertainty in the turnover 
and size of the PWID population. Approximately 30% of the variation was due to 
uncertainty in the temporary cessation rate amongst mid-term and long-term PWID, whilst 
uncertainty in the permanent cessation rate, injecting relapse rate and PWID population size 
contributed a further 16%, 10% and 10% to the variation, respectively (Supplementary 
Figure S5).
Discussion
Our model projections suggest that historical changes in intervention coverage and injecting 
risk pre-2008 would themselves have resulted in HCV incidence decreasing among PWID in 
Scotland, from approximately 14 per 100pyrs in 2008 to 10 per 100pyrs in 2015. 
Additionally, scaling-up opioid substitution therapy (OST) and needle and syringe provision 
(NSP) post-2008 contributed a further reduction in HCV incidence to 5 per 100pyrs by 
2015, and an estimated 1,400 HCV infections averted over 7-years. HCV treatment scale-up, 
however, has only had modest impact to date, averting an estimated 72 infections by 2015. 
This small impact of HCV treatment is both due to few (<5%) infected PWID being treated 
per year between 2008–2015, and HCV treatment only averting infections indirectly, first 
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through reducing prevalence and as a by-product reducing the risk that someone becomes 
infected from an infected PWID.
Strengths and limitations
The strengths of our modelling are that it was developed and parameterised using detailed 
data on the local epidemic and intervention coverage in Scotland, and was validated through 
its ability to mimic the changing epidemic patterns amongst PWID in Scotland between 
2008–2015, despite only being fitted to epidemiological data for 2008/09. However, 
limitations still exist.
First, the model did not simulate precisely all epidemiological trends from the NESI surveys. 
Model projections of HCV antibody-prevalence post-2008 tended to be lower than observed 
trends in Scotland. This may be due to more injectors continuing to inject than the model 
projected, thereby not fully capturing the long-term dynamics of injecting. Alternatively, the 
NESI survey may not be representative of all PWID, possibly through over sampling older 
PWID. Both factors could reduce the resulting observed impact of decreases in HCV 
incidence on reducing HCV prevalence overall, which is largely a product of population 
turnover. However, this would not affect the impact of intervention scale-up on more 
recently initiated PWID (which were simulated more accurately) where most new HCV 
infections occur.
Second, the counterfactual model also projected a decrease in HCV incidence. Figure S4 
shows that it agrees equally well with observed trends in HCV incidence as the intervention 
model, mainly due to the upturn in HCV incidence between 2011/12–2013/14 (NESI). This 
emphasises that without strong evidence for intervention scale-up over this period, it would 
have been impossible to decide whether the observed decreases in HCV incidence were due 
to improvements in intervention coverage or other historical changes.
Third, several model parameters were uncertain – including intervention effect estimates for 
OST and NSP, historical OST and NSP coverage, dynamics of high-risk behaviours, 
cessation and relapse rates, and the PWID prevalence in Scotland over time. Our projections 
incorporated uncertainty in all these parameters, and although they were robust despite this it 
did result in a low hit rate during the model calibration (581 of 5,000 model runs were a 
baseline model fit). Importantly, most imprecision resulted from uncertainty in the efficacy 
of NSP (alongside OST or not) and factors related to PWID population turnover and size, 
highlighting the need for better data on these quantities.
Finally, we assume that the decrease in high-risk behaviours in PWID is independent of the 
scale-up in harm reduction measures and treatment. Whilst evidence from Scotland and a 
recent Cochrane review shows that OST decreases the risk of HCV acquisition through 
reducing the frequency of injecting, independent of this, homelessness and stimulant 
injecting still increase the risk of HCV transmission in Scotland, as shown in a recent pooled 
analysis(49). It is possible that the increase in OST and or NSP coverage may have 
decreased the prevalence of high-risk behaviours, but due to a lack of data to support this it 
was not included as a model assumption.
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Comparison with other studies
Previous modelling studies have estimated the impact of OST, NSP (8,11–13) and HCV 
treatment(14,15,50,51) on HCV transmission at the population-level, but none have 
validated whether their projections are consistent with observed epidemiological data. In 
contrast, our model projections evaluate the evidence that increases in intervention coverage 
impacted on observed population-level HCV incidence trends. Evidence from Scotland 
shows that these interventions are associated with decreases in HCV acquisition risk at the 
individual-level, and that HCV incidence decreased at the population-level concurrently with 
their scale-up(5). However, these epidemiological analyses did not determine whether the 
observed decrease in incidence was consistent with the scale-up in intervention coverage; 
nor did they account for possible decreases in HCV transmission due to historical changes in 
intervention coverage and evolving epidemic dynamics. These are issues that modelling can 
address, as done in this analysis. Only one previous analysis has considered a similar 
question for HCV; modelling from Amsterdam showed that historical changes in risk 
behaviour prior to intervention scale-up contributed most to observed reductions in HCV 
incidence in Amsterdam(11).
Implications and Conclusions
Our model projections provide good evidence that the observed decline in HCV incidence in 
Scotland post-2008 was largely due to increased OST and NSP coverage, made possible 
through strategies implemented by the Scottish Government. These strategies provided 
dedicated funding for prevention(52), and set targets for improvements in services relating to 
injection equipment provision, HCV treatment, and treatment for addiction.
Our model projections also highlight uncertainty in the evidence base. Further data 
collection is needed to better evaluate the role of NSP in decreasing HCV transmission risk, 
preferably from multiple studies using comparable measures of coverage or intervention 
intensity(7,39). Additionally, more linkage studies are needed to better capture the natural 
history and transitions between injecting risk states for PWID populations(46,53,54). Both 
these factors contributed considerable uncertainty to our projections.
This study illustrates how a country-level HCV action plan incorporating scale-up of a range 
of HCV prevention interventions can markedly reduce HCV incidence. This contrasts 
sharply with most countries where restrictions in these interventions, due to funding 
limitations or legal constraints(55), severely limit their impact on HCV incidence(56–61). 
However, even with high OST and NSP coverage, the impact achieved in Scotland still falls 
short of the World Health Organisation’s strategy for reducing HCV incidence by 90%(62), 
highlighting that additional interventions are required to eliminate HCV. This could include 
scaling-up HCV treatment, which modelling has suggested could have substantial 
impact(12,50), and the scale-up of other interventions to reduce HCV transmission, such as: 
safe injecting facilities(63); expanding the use of low dead space syringes(64,65); or 
interventions such as prison-based OST to reduce the heightened risk associated with 
incarceration(66,67). This model could be an invaluable tool for determining which of these 
interventions are now needed to reduce HCV transmission to elimination levels in Scotland.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: 
Comparison of model projections with data on the scale-up of (a) OST coverage; (b) NSP 
coverage; (c) percentage of PWID that are high-risk; and (d) number of HCV treatments 
over time. In all graphs, black solid and dashed lines indicate the median projections for the 
581 baseline ‘intervention’ and counterfactual model runs, respectively, whereas light grey 
triangles indicate the mean (whiskers are 95% confidence intervals) estimates for the pre-
NESI data and dark grey circles indicate the mean (whiskers are 95% confidence intervals) 
estimates from different rounds of NESI or estimates from the period covered by NESI. Note 
that for NSP coverage, the upper intervals are bounded by the mean self-reported NSP 
coverage from NESI.
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Figure 2: 
Model and NESI estimated HCV incidence (figures (a) and (b)) and anti-HCV prevalence 
(figures (c) and (d)) amongst PWID. (a) HCV incidence amongst all current injectors (b) 
HCV incidence amongst short-term current injectors (injecting <1yrs), (c) Anti-HCV 
prevalence amongst all current injectors, and (d) Anti-HCV prevalence amongst short-term 
current injectors (injecting <1 yrs). In all graphs, black solid lines indicate the median 
projections for the 581 baseline ‘intervention’ model runs. The light grey triangles indicate 
the mean (whiskers are 95% CI) data estimates from NESI which were fit too and the dark 
grey circles indicate the mean (whiskers are 95% CI) data estimates from NESI that were 
not fit to. Note: Anti-HCV prevalence was fit to a wider range of 49–57%.
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Figure 3: 
A comparison of NESI HCV incidence estimates for different years (grey and black points) 
with the model projected HCV incidence amongst all PWID (median across all full model 
fits) for different intervention scenarios: no intervention scale-up or decrease in high-risk 
behaviour from 2008 onwards (light grey line – full counterfactual); Scale up of OST and 
high coverage NSP only from 2008 onwards (dark grey line); Scale up of OST and high 
coverage NSP plus decrease in high risk behaviour from 2008 onwards (single dashed line); 
Scale up of all interventions from 2008 onwards (dash and dotted line – baseline 
intervention runs). Whiskers denote the 95% CI for each NESI HCV incidence estimate.
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Table 2:
Infections averted amongst people who inject drugs and the relative decrease in incidence between 2008 and 
2015 for the different scenarios of interventions being scaled-up from 2008. Ranges in brackets are 95% 
credibility intervals.
Change from 2008 to 2015 compared to
counterfactual
Mean number
of infections
Mean infections
averted (95% CrI)
Mean relative
decrease in incidence
No change (i.e. no intervention scale-up or
decrease in proportion high-risk)
6353
(3450–9728)
N/A 27.4% (17.6−37.0%)
Scale-up of OST and high coverage NSP
only
5337
(3035–8329)
1016 (308−1996) 47.3% (30.0−62.7%)
Scale-up of OST and high coverage NSP plus
decrease in high-risk status
4933
(2714–7767)
1420 (613−2544) 57.9% (41.1−72.3%)
Scale-up of OST and high coverage NSP plus
decrease in high risk status plus increase in
HCV treatment
4861
(2646–7681)
1492 (657−2646) 61.3% (45.1−75.3%)
Projections are means of model fits, with 95% credibility intervals in brackets
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